Intellia Therapeutics Quarterly Cash Flow Statement
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Intellia Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Intellia Therapeutics generated -$83.1 million of operating cash flow and spent $1.8 million on capital expenditures. That left free cash flow of -$84.9 million, a free-cash-flow margin of -1108.8% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Intellia Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -106.63M | -96.23M | -95.79M | -101.32M | -101.25M | -114.33M | -128.90M | -135.71M | -146.97M | -107.44M | -132.16M | -122.22M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.10M | 2.20M | 2.38M | 2.40M | 2.50M | 2.50M | 2.57M | 2.60M | 2.60M | 2.51M | 2.47M | 2.29M |
| Stock-Based Compensation | 18.07M | 13.48M | 16.74M | 19.60M | 22.04M | 21.84M | 39.62M | 39.62M | 40.86M | 34.18M | 35.04M | 35.35M |
| Change in Working Capital | 1.06M | -19.76M | 5.53M | 23.43M | -17.30M | -37.19M | -678.00K | -1.35M | 26.67M | -21.45M | 18.06M | -8.74M |
| Operating Cash Flow | -83.11M | -117.35M | -69.28M | -76.90M | -99.62M | -148.93M | -85.19M | -84.84M | -58.19M | -120.66M | -93.05M | -101.38M |
| Capital Expenditures | -1.81M | -79.00K | -126.00K | -29.00K | -239.00K | -735.00K | -981.00K | -1.28M | -1.01M | -2.51M | -1.52M | -4.33M |
| Investing Cash Flow | -141.57M | 66.31M | 27.53M | -741.00K | 106.91M | 94.33M | 151.56M | -7.71M | -24.19M | 5.90M | 45.94M | 79.50M |
| Financing Cash Flow | 196.12M | 33.57M | 1.98M | 114.86M | 14.65M | 0 | 2.32M | 82.19M | 41.25M | 59.99M | 106.48M | 19.10M |
| Net Change in Cash | -28.57M | -17.47M | -39.77M | 37.22M | 21.94M | -54.60M | 68.69M | -10.35M | -41.13M | -54.77M | 59.37M | -2.78M |
| Free Cash Flow | -84.92M | -117.42M | -69.41M | -76.93M | -99.86M | -149.66M | -86.18M | -86.12M | -59.20M | -123.17M | -94.57M | -105.71M |
This table shows 12 quarterly periods of Intellia Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NTLA's reporting calendar. What is a cash flow statement?